4
Changes in Ownership
Oruka Therapeutics, Inc. Filed Acc 0000907654-26-000041
Senior Vice President, Finance sold 10,290 shares at an average $59.07 ($607,806)
- Senior Vice President, Finance acquired 7,833 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Agarwal Arjun · Senior Vice President, Finance
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-05-18 | Exercise or conversion : show line 1 in the form 10b5-1 | +2,000 | $12.50 | $25,000 | 20,863 | D |
| 2026-05-18 | Exercise or conversion : show line 2 in the form 10b5-1 | +5,833 | $34.39 | $200,597 | 26,696 | D |
| 2026-05-18 | Sale : show line 3 in the form 10b5-1 | −4,190 | $58.34 | $244,465 | 22,506 | D |
| 2026-05-18 | Sale : show line 4 in the form 10b5-1 | −4,600 | $59.19 | $272,260 | 17,906 | D |
| 2026-05-18 | Sale : show line 5 in the form 10b5-1 | −800 | $60.34 | $48,269 | 17,106 | D |
| 2026-05-18 | Sale : show line 6 in the form 10b5-1 | −700 | $61.16 | $42,812 | 16,406 | D |
| Open-market sales · 10,290 sh · avg $59.07 · $607,806 | ||||||
Table II: Derivative
2 lines| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-05-18 | Exercise or conversion : show line 7 in the form 10b5-1 Employee Stock Option (right to buy) | −2,000 | 118,000 | D |
| 2026-05-18 | Exercise or conversion : show line 8 in the form 10b5-1 Employee Stock Option (right to buy) | −5,833 | 64,167 | D |
Loading xslF345X06/form4.xml…